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ABOUT THE JOURNAL 
 
 
Aims and Scope 
Blood Cancer Journal is an online only, open access journal from 
Nature Publishing Group seeking to publish articles of the highest 
quality related to hematologic malignancies and related disorders.  
The Journal will consider for publication original research, reviews, 
guidelines and letters that are considered to be of high impact in 
the field.   
 
Topics of particular interest include, but are not limited to, the 
following: 
 
 Preclinical studies of new compounds, especially those 
that provide mechanistic insights  
 Clinical trials and observations 
 Reviews related to new drugs and current management of 
hematologic malignancies  
 Novel observations related to new mutations, molecular 
pathways, and tumor genomics  
 
Journal Details 
Editors:  
S. Vincent Rajkumar, MD 
Mayo Clinic, Rochester, Minnesota, USA  
Ayalew Tefferi, MD 
Mayo Clinic, Rochester, Minnesota, USA  
 
 
Editorial office:  
Nature Publishing Group, The Macmillan Building  
4 Crinan Street 
London, UK   
bcj@nature.com  
 
Impact Factor: 4.411(2015 Journal Citation Reports, Thomson Reuters, 
2015). 
 
Editorial Note 
 
The types of communication published in Blood Cancer Journal reflect 
the mission of the journal to promote an effective transfer of results 
and ideas from bench to clinic and the reverse. Authors should 
therefore make their manuscripts as accessible as possible, by 
keeping the needs of this broad-ranging audience in mind.  
Blood Cancer Journal has at heart a desire not to expose authors to 
protracted reviewing periods that sometimes, unfortunately, result 
in rejection. To this end, we endeavour to provide you with a very 
rapid answer in the case of rejection; that is, 5 to 15 days after 
submission. Naturally, this may mean manuscripts are returned to 
authors without refereeing. This decision, however, is always made 
on the basis of a thorough scrutiny of each manuscript by the Editor.  
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ARTICLE TYPE SPECIFICATIONS 
 
ARTICLE DESCRIPTION ABSTRACT  WORD LIMIT TABLES/ 
FIGURES 
REFERENCES 
Original Articles  
Please see ‘Preparation of Original Articles’ below for 
further details 
 
 
Unstructured abstract, 
max 200 words 
 
 
4,500 words max 
excluding abstract, 
references, figures 
and tables.  
Max of 8  Max of 60 
 
Reviews  
Reviews are comprehensive analyses of specific topics. 
These should clearly indicate how conclusions are drawn 
from the data. 
Unstructured abstract, 
max 300 words 
 
 
5,000 words max 
excluding abstract, 
references, figures 
and tables.  
Max of 8 Max of 100 
Letters to the Editor 
They must be written in the style of a letter with the title at 
the top of the page and Letter to the Editor underneath. All 
authors' names and affiliations must be at the end of the 
manuscript (including Corresponding author's full address, 
telephone and fax numbers). Processing remains at the 
discretion of the Editors, and the Authors are immediately 
informed. The response is very rapid. 
No abstract required. 1,500 words max 
excluding 
references, figures 
and tables.  
Max of 2 Max of 15 
Editorials (by Editor invitation only) 
Proposals for Editorials may be submitted; authors should 
only send an outline of the proposed paper for initial 
consideration. 
No abstract required. 1,200 words 
excluding 
references, figures 
and tables. 
Max of 2 Max of 15 
Meeting Reports  
Please contact the Editors-in-Chief. Occasionally we 
publish, for a fee, abstracts for Meetings. We usually ask for 
a commentary from the organisers summarising the data 
contained in the abstracts. 
    
 
 
 
 
PREPARATION OF ARTICLES 
 
 
Please note that original articles must contain the following 
components. Please see below for further details.  
 
 Cover letter  
 Title page (excluding acknowledgements) 
 Abstract  
 Introduction 
 Materials (or Subjects) and Methods 
 Results 
 Discussion 
 Acknowledgements 
 Conflict of Interest 
 References 
 Figure legends 
 Tables 
 Figures 
 
Cover Letter: The uploaded covering letter must state the material 
is original research, has not been previously published and has not 
been submitted for publication elsewhere while under 
consideration. If the manuscript has been previously considered for 
publication in another journal, please include the previous reviewer 
comments, to help expedite the decision by the Editorial team. 
Add note about including conflict of interest statement. 
 
Title Page: The title page should bear the title of the paper, the full 
names of all the authors and their affiliations, together with the 
name, full postal address, telephone and fax numbers and e-mail 
address of the author to whom correspondence and offprint 
requests are to be sent (this information is also asked for on the 
electronic submission form). The title page must also contain a 
Conflict of Interest statement (see Editorial Policy section). 
 
 The title should be brief, informative, of 150 characters or less 
and should not make a statement or conclusion.  
 The running title should consist of no more than 50 letters 
and spaces. It should be as brief as possible, convey the 
essential message of the paper and contain no abbreviations.  
 Authors should disclose the sources of any support for the 
work, received in the form of grants and/or equipment and 
drugs. 
 If authors regard it as essential to indicate that two or more 
co-authors are equal in status, they may be identified by an 
asterisk symbol with the caption ‘These authors contributed 
equally to this work’ immediately under the address list. 
 
Abstract: Original Articles must be prepared with an unstructured 
abstract designed to summarise the essential features of the paper in 
a logical and concise sequence. 
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Materials/Subjects and Methods: This section should contain 
sufficient detail, so that all experimental procedures can be 
reproduced, and include references. Methods, however, that have 
been published in detail elsewhere should not be described in 
detail. Authors should provide the name of the manufacturer and 
their location for any specifically named medical equipment and 
instruments, and all drugs should be identified by their 
pharmaceutical names, and by their trade name if relevant. 
 
Results and Discussion: The Results section should briefly present 
the experimental data in text, tables or figures. Tables and figures 
should not be described extensively in the text, either. The 
discussion should focus on the interpretation and the significance 
of the findings with concise objective comments that describe their 
relation to other work in the area. It should not repeat information 
in the results. The final paragraph should highlight the main 
conclusion(s), and provide some indication of the direction future 
research should take. 
 
Acknowledgements: These should be brief, and should include  
sources of support including sponsorship (e.g. university, charity, 
commercial organisation) and sources of material (e.g. novel drugs) 
not available commercially. 
 
Conflict of Interest: Authors must declare whether or not there are 
any competing financial interests in relation to the work described. 
This information must be included at this stage and will be 
published as part of the paper. Conflict of interest should be noted 
in the cover letter and also on the title page. Please see the Conflict 
of Interest documentation in the Editorial Policy section for detailed 
information. 
 
References: Only papers directly related to the article should be 
cited. Exhaustive lists should be avoided. References should follow 
the Vancouver format. In the text they should appear as numbers 
starting at one and at the end of the paper they should be listed 
(double-spaced) in numerical order corresponding to the order of 
citation in the text. Where a reference is to appear next to a number 
in the text, for example following an equation, chemical formula or 
biological acronym, citations should be written as (ref. X) and not 
as superscript. 
Example. ‚detectable levels of endogenous Bcl-2 (ref. 3), as 
confirmed by western blot‛ 
 
All authors should be listed for papers with up to six authors; for 
papers with more than six authors, the first six only should be 
listed, followed by et al. Abbreviations for titles of medical 
periodicals should conform to those used in the latest edition of 
Index Medicus. The first and last page numbers for each reference 
should be provided. Abstracts and letters must be identified as 
such. Papers in press may be included in the list of references. 
 
Personal communications must be allocated a number and included 
in the list of references in the usual way or simply referred to in the 
text; the authors may choose which method to use. In either case 
authors must obtain permission from the individual concerned to 
quote his/her unpublished work. 
 
Examples: 
Journal article, up to six authors: 
Belkaid Y, Rouse BT. Natural regulatory T cells in infectious 
disease. Nat Immunol 2005; 6: 353–360. 
 
Journal article, e-pub ahead of print: 
Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G et 
al. F-ara-A pharmacokinetics during reduced-intensity conditioning 
therapy with fludarabine and busulfan. Bone Marrow 
Transplant 2007; e-pub ahead of print 8 January 2007; 
doi:10.1038/sj.bmt.1705565 
 
Journal article, in press: 
Gallardo RL, Juneja HS, Gardner FH. Normal human marrow 
stromal cells induce clonal growth of human malignant T-
lymphoblasts. Int J Cell Cloning (in press). 
 
Complete book: 
Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner MK 
(eds). Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd 
edn. Cambridge University Press: Cambridge, UK, 2004. 
 
Chapter in book: 
Coccia PF. Hematopoietic cell transplantation for osteopetrosis. In: 
Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic 
Cell Transplantation, 3rd edn. Blackwell Publishing Ltd: Malden, 
MA, USA, 2004, pp 1443–1454. 
 
Abstract: 
Syrjala KL, Abrams JR, Storer B, Heiman JR. Prospective risk factors 
for five-year sexuality late effects in men and women after 
haematopoietic cell transplantation. Bone Marrow 
Transplant 2006; 37(Suppl 1): S4 (abstract 107). 
 
Correspondence: 
Caocci G, Pisu S. Overcoming scientific barriers and human 
prudence [letter]. Bone Marrow Transplant 2006; 38: 829–830. 
 
Figure Legends: These should be brief, specific and appear on a 
separate manuscript page after the References section.  
 
Tables: Tables should only be used to present essential data; they 
should not duplicate what is written in the text. It is imperative 
that any tables used are editable, ideally presented in Excel.  Each 
must be uploaded as a separate workbook with a title or caption 
and be clearly labelled, sequentially. Please make sure each table is 
cited within the text and in the correct order, e.g. (Table 3). 
Please save the files with extensions .xls / .xlsx / .ods / or .doc or 
.docx. Please ensure that you provide a 'flat' file, with single values 
in each cell with no macros or links to other workbooks or 
worksheets and no calculations or functions. 
 
Figures: Figures and images should be labelled sequentially and 
cited in the text. Figures should not be embedded within the text 
but rather uploaded as separate files. Detailed guidelines for 
submitting artwork can be found by downloading our Artwork 
Guidelines. The use of three-dimensional histograms is strongly 
discouraged when the addition of the third dimension gives no 
extra information.  
 
Reuse of Display Items: See the Editorial Policy section for 
information on using previously published tables or figures.  
 
Supplementary Information: Supplementary information (SI) is 
peer-reviewed material directly relevant to the conclusion of an 
article that cannot be included in the printed version owing to space 
or format constraints. The article must be complete and self-
explanatory without the SI, which is posted on the journal's website 
and linked to the article. SI may consist of data files, graphics, 
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movies or extensive tables. Please see our Artwork Guidelines for 
information on accepted file types.  
 
Authors should submit supplementary information files in the 
FINAL format as they are not edited, typeset or changed, and will 
appear online exactly as submitted. When submitting SI, authors 
are required to:  
 
 Include a text summary (no more than 50 words) to describe 
the contents of each file. 
 Identify the types of files (file formats) submitted. 
 Include the text ‚Supplementary information is available at 
(journal name)’s website‛ at the end of the article and before 
the references. 
 
Availability of Data and Materials: Please see our Editorial 
Policies for information regarding data, protocols, sequences, or 
structures.  
 
Subject Ontology: Choosing the most relevant and specific subject 
terms from our subject ontology will ensure that your article will be 
more discoverable and will appear on appropriate subject specific 
pages on nature.com, in addition to the journal’s own pages.  Your 
article should be indexed with at least one, and up to four unique 
subject terms that describe the key subjects and concepts in your 
manuscript.  Click here for help with this. 
 
House Style 
 Text should be double spaced with a wide margin. 
 All pages and lines are to be numbered.  To add page 
numbers in MS Word, go to Insert then Page Numbers. To 
add line numbers go to File, Page Setup, then click 
the Layout tab. In the Apply to box, select Whole document, 
click Line Numbers then select the Add line 
numbering check box, followed by Continuous. 
 Do not make rules thinner than 1pt (0.36mm). 
 Use a coarse hatching pattern rather than shading for tints in 
graphs. 
 Colour should be distinct when being used as an identifying 
tool. 
 Spaces, not commas should be used to separate thousands. 
 At first mention of a manufacturer, the town (and state if 
USA) and country should be provided.  
 Statistical methods: For normally distributed data, mean (SD) 
is the preferred summary statistic. Relative risks should be 
expressed as odds ratios with 95% confidence interval. To 
compare two methods for measuring a variable the method 
of Bland & Altman (1986, Lancet 1, 307–310) should be used; 
for this, calculation of P only is not appropriate. 
 Units: Use metric units (SI units) as fully as possible. 
Preferably give measurements of energy in kiloJoules or 
MegaJoules with kilocalories in parentheses (1 kcal = 4.186kJ). 
Use % throughout.  
 Abbreviations: On first using an abbreviation place it in 
parentheses after the full item. Very common abbreviations 
such as FFA, RNA, need not be defined. Note these 
abbreviations: gram g; litre l; milligram mg; kilogram kg; 
kilojoule kJ; megajoule MJ; weight wt; seconds s; 
minutes min; hours h. Do not add s for plural units. 
 
English Language Support 
For editors and reviewers to accurately assess the work presented in 
your manuscript you need to ensure the English language is of 
sufficient quality to be understood. If you need help with writing in 
English you should consider: 
 
 Asking a colleague who is a native English speaker to review 
your manuscript for clarity.  
 Visiting the English language tutorial which covers the 
common mistakes when writing in English. 
 Using a professional language editing service where editors 
will improve the English to ensure that your meaning is clear 
and identify problems that require your review. Two such 
services are provided by our affiliates Nature Research 
Editing Service and American Journal Experts. 
 
Please note that the use of a language editing service is not a 
requirement for publication in this journal and does not imply or 
guarantee that the article will be selected for peer review or 
accepted. 
 
If your manuscript is accepted it will be checked by our copyeditors 
for spelling and formal style before publication.
 
 
HOW TO SUBMIT 
 
 
Pre-submission Enquiries  
Pre-submission enquiries should be submitted via the online 
submission system.  All other pre-submission enquiries should be 
directed to the editorial office:  
Email: bcj@nature.com    
 
Online Submission 
We only accept manuscript submission via our online manuscript 
submission system. Before submitting a manuscript, authors are 
encouraged to consult both our Editorial Policies and the 
Submission Instructions for our online manuscript submission 
system. If you have not already done so, please register for an 
account with our online manuscript system.  
You will be able to monitor the status of your manuscript online 
throughout the editorial process.  
 
Submission of Revisions 
Authors submitting a revised manuscript after review are asked to 
include the following: 
 
(1) A rebuttal letter, indicating point-by-point how you have 
addressed the comments raised by the reviewers. If you 
disagree with any of the points raised, please provide 
adequate justification in your letter.   
(2) A marked-up version of the manuscript that highlights 
changes made in response to the reviewers' comments in order 
to aid the Editors and reviewers.  
(3) A 'clean' (non-highlighted) version of the manuscript.
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POST-ACCEPTANCE 
 
 
Blood Cancer Journal is an open access journal: authors pay an 
article processing charge (APC) for their accepted articles to be 
open access online and freely accessible, immediately upon 
publication, under a Creative Commons license. 
 
Visit our open research site for further information about licenses, 
APCs, and our free OA funding support service: 
 
 About Creative Commons licensing 
 Creative Commons license options and article processing 
charges (APCs) for Blood Cancer Journal 
 APC payment FAQs 
 Help in identifying funding for APCs 
 APC waiver policy 
 Compliance with funding body requirements  
 
Once a manuscript is accepted the corresponding author must 
complete an Article Processing Charge (APC) payment form and 
an open access License to Publish (LTP) form on behalf of all 
authors, and return these to the editorial office. Forms will be 
provided upon acceptance of the article. Failure to promptly 
return forms will result in delay of publication. 
 
Government employees from the United States and UK are 
required to sign and submit the relevant government open access 
license to publish form. 
Please note with regards to payment that usual credit terms are 30 
days from receipt of invoice. Failure to pay your invoice within the 
stated credit term may result in such penalties as restrictions on 
your ability to publish with Nature Publishing Group or Blood 
Cancer Journal in the future, involvement of a third Party debt 
collection agency and legal proceedings. 
 
Manuscript deposition and self-archiving 
To facilitate self-archiving NPG deposits open access articles in 
PubMed Central and Europe PubMed Central on publication. 
Authors are also permitted to post the final, published PDF of 
their article on a website, institutional repository or other free 
public server, immediately on publication. Learn more about self-
archiving and deposition of papers published OA. 
 
Proofs  
The corresponding author will receive an e-mail containing a URL 
linking to the proofing site. Proof corrections must be returned 
within 48 hours of receipt. Failure to do so may result in delayed 
publication. Extensive corrections cannot be made at this stage.
 
 
 
COSTS 
 
 
Blood Cancer Journal levies the following Article-Processing Charges (APC) per article accepted for publication. A payment form will need to be 
completed and returned alongside the License to Publish form. Failure to promptly return these forms will result in delay of publication.   
With regards to payment, usual credit terms are 30 days from receipt of invoice. Failure to pay your invoice within the stated credit term may 
result in restrictions on your ability to publish with Nature Publishing Group or Blood Cancer Journal in the future, involvement of a third party 
debt collection agency and legal proceedings. 
 
 UK & RoW US Europe 
Original article / Unsolicited Review / Meeting Reports £2,700 $3,500 €2,900 
Correspondence/Letter to the Editor £900 $1,100 €1,000 
Solicited Article/Review/Editorial Free of charge Free of charge Free of charge 
(VAT or local taxes will be added where applicable) 
 
Fee Waiver Policy 
 
We offer APC waivers to authors from HINARI countries. Discretionary APC waivers will be considered on a case-by-case basis and may be 
granted in cases of financial need. All applications for APC waivers should be made prior to, or at the point of, manuscript submission; requests 
made during the review process or after acceptance will not be considered. To request a waiver, please contact us at 
apcwaivers@springernature.com. 
 
Open access funding 
Visit Nature Publishing Group's open access funding page for information about research funders and institutions that provide funding for 
open access. 
 
NPG also offers an APC support service to make it easier for NPG authors to discover and apply for open access funding. For advice on what 
funding is available to you and help in approaching funders and institutions, please contact us at apcwaivers@springernature.com. 
 
For more information about NPG's open access publishing options and policies, please see our open access homepage. 
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EDITORIAL POLICIES 
 
Duplicate Publication 
Papers must be original and not published or submitted for 
publication elsewhere. This rule also applies to non-English 
language publications. NPG allows and encourages prior 
publication on recognized community preprint servers for review 
by other scientists before formal submission to a journal. The 
details of the preprint server concerned and any accession numbers 
should be included in the cover letter accompanying manuscript 
submission. This policy does not extend to preprints available to 
the media or that are otherwise publicized outside the scientific 
community before or during the submission and consideration 
process. 
 
Permissions 
If a table or figure has been published before, the authors must 
obtain written permission to reproduce the material in both print 
and electronic formats from the copyright owner and submit it with 
the manuscript. This follows for quotes, illustrations and other 
materials taken from previously published works not in the public 
domain. The original source should be cited in the figure caption or 
table footnote.  
 
Clinical Trials 
As defined by the International Committee of Medical Journal 
Editors (ICMJE), a clinical trial is any research project that 
prospectively assigns human subjects to intervention and 
comparison groups to study the cause-and-effect relationship 
between a medical intervention and a health outcome. A medical 
intervention is any intervention used to modify a health outcome 
and includes but is not limited to drugs, surgical procedures, 
devices, behavioural treatments, and process-of-care changes. A 
trial must have at least one prospectively assigned concurrent 
control or comparison group in order to trigger the requirement for 
registration. Nonrandomized trials are not exempt from the 
registration requirement if they meet the above criteria. 
 
When reporting experiments on human subjects, please indicate 
whether the procedures were in accordance with the ethical 
standards of the responsible committee on human experimentation 
(institutional or regional) or with the Helsinki Declaration of 1975 
(as revised in 1983).  Include Institutional Review Board or Animal 
Care and Use Committee approvals. 
 
All clinical trials must be registered in a public registry prior to 
submission. The journal follows the trials registration policy of the 
ICMJE (www.icmje.org) and considers only trials that have been 
appropriately registered before submission, regardless of when the 
trial closed to enrolment. Acceptable registries must meet the 
following ICMJE requirements:  
 be publicly available, searchable, and open to all prospective 
registrants  
 have a validation mechanism for registration data  
 be managed by a not-for-profit organization  
 
Examples of registries that meet these criteria include:  
 
1) the registry sponsored by the United States National Library 
of Medicine (www.clinicaltrials.gov);  
2) the International Standard Randomized Controlled Trial 
Number Registry (www.controlled-trials.com);  
3) the Cochrane Renal Group Registry (www.cochrane-
renal.org);  
4) and the European Clinical Trials Database 
(https://eudract.ema.europa.eu/). 
 
The trial registry number for eligible papers will be collected during 
the submission process. 
 
Randomised Controlled Trials (RCTs) must adhere to the 
CONSORT statement, (CONsolidated Standards Of Reporting 
Trials) and submissions must be accompanied by a completed 
CONSORT checklist (uploaded as a related manuscript file). Further 
information can be found at www.consort-statement.org. 
 
Nature Publishing Group endorses the toolkits and guidelines 
produced by the Committee on Publication Ethics (COPE): 
http://publicationethics.org/  
 
Conflict of Interest 
In the interests of transparency and to help readers form their own 
judgments of potential bias, authors must declare whether or not 
there are any competing financial interests in relation to the work 
described. This information must be included in their cover letter 
and on the title page of their manuscript. In cases where the authors 
declare a competing financial interest, a statement to that effect is 
published as part of the article. If no such conflict exists, the 
statement will simply read that the authors have nothing to 
disclose. 
 
For the purposes of this statement, competing interests are defined 
as those of a financial nature that, through their potential influence 
on behaviour or content, or from perception of such potential 
influences, could undermine the objectivity, integrity or perceived 
value of a publication. They can include any of the following:  
 
 Funding: Research support (including salaries, equipment, 
supplies, reimbursement for attending symposia, and other 
expenses) by organizations that may gain or lose financially 
through this publication. The role of the funding body in the 
design of the study, collection and analysis of data and 
decision to publish should be stated. 
 Employment: Recent (while engaged in the research project), 
present or anticipated employment by any organization that 
may gain or lose financially through this publication. 
 Personal financial interests: Stocks or shares in companies 
that may gain or lose financially through publication; 
consultation fees or other forms of remuneration from 
organizations that may gain or lose financially; patents or 
patent applications whose value may be affected by 
publication.  
 
It is difficult to specify a threshold at which a financial interest 
becomes significant, but note that many US universities require 
faculty members to disclose interests exceeding $10,000 or 5% 
equity in a company. Any such figure is arbitrary, so we offer as 
one possible practical alternative guideline: "Declare all interests 
that could embarrass you were they to become publicly known after 
your work was published." We do not consider diversified mutual 
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funds or investment trusts to constitute a competing financial 
interest.  
 
The statement must contain an explicit and unambiguous statement 
describing any potential conflict of interest, or lack thereof, for any 
of the authors as it relates to the subject of the report. Examples 
include ‚Dr. Smith receives compensation as a consultant for XYZ 
Company,‛ ‚Dr. Jones and Dr. Smith have financial holdings in 
ABC Company,‛ or ‚Dr. Jones owns a patent on the diagnostic 
device described in this report.‛ These statements acknowledging 
or denying conflicts of interest must be included in the manuscript 
under the heading Conflict of Interest. The Conflict of Interest 
disclosure appears in the cover letter, in the manuscript submission 
process and before the References section in the manuscript. 
 
Following the Conflict of Interest heading, there must be a listing 
for each author, detailing the professional services relevant to the 
submission. Neither the precise amount received from each entity 
nor the aggregate income from these sources needs to be provided. 
Professional services include any activities for which the individual 
is, has been, or will be compensated with cash, royalties, fees, stock 
or stock options in exchange for work performed, advice or counsel 
provided, or for other services related to the author’s professional 
knowledge and skills. This would include, but not necessarily be 
limited to, the identification of organizations from which the author 
received contracts or in which he or she holds an equity stake if 
professional services were provided in conjunction with the 
transaction. 
 
Examples of declarations are:  
 
 Conflict of interest. 
The authors declare no conflict of interest. 
 Conflict of interest. 
Dr Caron's work has been funded by the NIH. He has 
received compensation as a member of the scientific advisory 
board of Acadia Pharmaceutical and owns stock in the 
company. He also has consulted for Lundbeck and received 
compensation. Dr Rothman and Dr Jensen declare no 
potential conflict of interest. 
 
Authorship  
Requirements for all categories of articles should conform to the 
‚Uniform Requirements for Manuscripts Submitted to Biomedical 
Journals,‛ developed by the ICMJE (www.icmje.org).  
 
Each author must have contributed sufficiently to the intellectual 
content of the submission. The corresponding author should list all 
authors and their contributions to the work. Any changes to the 
author list after submission, such as a change in the order of the 
authors, or the deletion or addition of authors, must be approved 
by a signed letter from every author. The corresponding author 
must confirm that he or she has had full access to the data in the 
study and final responsibility for the decision to submit for 
publication. To qualify as a contributing author, one must meet all 
of the following criteria: 
 
1) Conceived and/or designed the work that led to the 
submission, acquired data, and/or played an important role 
in interpreting the results. 
2) Drafted or revised the manuscript. 
3) Approved the final version. 
 
Contributions by individuals who made direct contributions to the 
work but do not meet all of the above criteria should be noted in the 
Acknowledgments section of the manuscript.  Medical writers and 
industry employees can be contributors. Their roles, affiliations, and 
potential conflicts of interest should be included in the author list or 
noted in the Acknowledgments and/or Contributors section 
concurrent with their contribution to the work submitted. Signed 
statements from any medical writers or editors declaring that they 
have given permission to be named as an author, as a contributor, 
or in the Acknowledgments section is also required.  Failure to 
acknowledge these contributors can be considered inappropriate, 
which conflicts with the journal’s editorial policy. 
 
Reproducibility 
As of March 2015, Blood Cancer Journal requires authors of papers 
that are sent for external review to include in their manuscripts 
relevant details about several elements of experimental and 
analytical design. This initiative aims to improve the transparency 
of reporting and the reproducibility of published results, focusing 
on elements of methodological information that are frequently 
poorly reported. Authors being asked to resubmit a manuscript will 
be asked to confirm that these elements are included by filling out a 
checklist that will be made available to the editor and reviewers. 
 
Correspondence with the Journal 
One author is designated the contact author for matters arising from 
the manuscript (materials requests, technical comments and so on). 
It is this author's responsibility to inform all co-authors of matters 
arising and to ensure such matters are dealt with promptly. Before 
submission, the corresponding author ensures that all authors are 
included in the author list, its order agreed upon by all authors, and 
are aware that the manuscript was submitted.  After acceptance for 
publication, proofs are e-mailed to this corresponding author who 
should circulate the proof to all co-authors and coordinate 
corrections among them 
 
Plagiarism and Fabrication 
CrossCheck is a multi-publisher initiative to screen published and 
submitted content for originality. NPG Journals use CrossCheck to 
detect instances of overlapping and similar text in submitted 
manuscripts. To find out more about CrossCheck 
visit www.crossref.org/crosscheck.html. 
 
Plagiarism is when an author attempts to pass off someone else's 
work as his or her own. Duplicate publication, sometimes called 
self-plagiarism, occurs when an author reuses substantial parts of 
his or her own published work without providing the appropriate 
references. Minor plagiarism without dishonest intent is relatively 
frequent, for example, when an author reuses parts of an 
introduction from an earlier paper.  
 
If plagiarism is found, the journal will contact the author's institute 
and funding agencies. The paper containing the plagiarism will be 
marked on each page of the PDF and depending on the extent of the 
plagiarism, a published article may also be formally retracted. 
 
Image Integrity and Standards 
Images submitted with a manuscript for review should be 
minimally processed (for instance, to add arrows to a micrograph). 
Authors should retain their unprocessed data and metadata files, as 
editors may request them to aid in manuscript evaluation. If 
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unprocessed data is unavailable, manuscript evaluation may be 
stalled until the issue is resolved.  
 
A certain degree of image processing is acceptable for publication, 
but the final image must correctly represent the original data and 
conform to community standards. The guidelines below will aid in 
accurate data presentation at the image processing level:  
 
 Authors should list all image acquisition tools and image 
processing software packages used. Authors should 
document key image-gathering settings and processing 
manipulations in the Methods section. 
 Images gathered at different times or from different locations 
should not be combined into a single image, unless it is 
stated that the resultant image is a product of time-averaged 
data or a time-lapse sequence. If juxtaposing images is 
essential, the borders should be clearly demarcated in the 
figure and described in the legend. 
 Touch-up tools, such as cloning and healing tools in 
Photoshop, or any feature that deliberately obscures 
manipulations, is to be avoided. 
 Processing (such as changing brightness and contrast) is 
appropriate only when it is applied equally across the entire 
image and is applied equally to controls. Contrast should not 
be adjusted so that data disappear. Excessive manipulations, 
such as processing to emphasize one region in the image at 
the expense of others (for example, through the use of a 
biased choice of threshold settings), is inappropriate, as is 
emphasizing experimental data relative to the control. 
 
For gels and blots, positive and negative controls, as well as 
molecular size markers, should be included on each gel and blot – 
either in the main figure or an expanded data supplementary 
figure. The display of cropped gels and blots in the main paper is 
encouraged if it improves the clarity and conciseness of the 
presentation. In such cases, the cropping must be mentioned in the 
figure legend.  
 Vertically sliced gels that juxtapose lanes that were not 
contiguous in the experiment must have a clear separation or 
a black line delineating the boundary between the gels. 
 Cropped gels in the paper must retain important bands. 
 Cropped blots in the body of the paper should retain at least 
six band widths above and below the band. 
 High-contrast gels and blots are discouraged, as 
overexposure may mask additional bands. Authors should 
strive for exposures with gray backgrounds. Immunoblots 
should be surrounded by a black line to indicate the borders 
of the blot, if the background is faint. 
 For quantitative comparisons, appropriate reagents, controls 
and imaging methods with linear signal ranges should be 
used. 
 
Microscopy adjustments should be applied to the entire image. 
Threshold manipulation, expansion or contraction of signal ranges 
and the altering of high signals should be avoided. If ‘pseudo-
colouring’ and nonlinear adjustment (for example ‘gamma 
changes’) are used, this must be disclosed. Adjustments of 
individual colour channels are sometimes necessary on ‘merged’ 
images, but this should be noted in the figure legend. We 
encourage inclusion of the following with the final revised version 
of the manuscript for publication:  
 
 In the Methods section, specify the type of equipment 
(microscopes/objective lenses, cameras, detectors, filter model 
and batch number) and acquisition software used. Although 
we appreciate that there is some variation between 
instruments, equipment settings for critical measurements 
should also be listed. 
 The display lookup table (LUT) and the quantitative map 
between the LUT and the bitmap should be provided, 
especially when rainbow pseudo-colour is used. It should be 
stated if the LUT is linear and covers the full range of the 
data. 
 Processing software should be named and manipulations 
indicated (such as type of deconvolution, three-dimensional 
reconstructions, surface and volume rendering, 'gamma 
changes', filtering, thresholding and projection). 
 Authors should state the measured resolution at which an 
image was acquired and any downstream processing or 
averaging that enhances the resolution of the image. 
 
Availability of Data and Materials 
An inherent principle of publication is that others should be able to 
replicate and build upon the authors’ published claims. Therefore, a 
condition of publication is that authors are required to make 
materials, data, and associated protocols available in a publicly 
accessible database. Where one does not exist, the information must 
be made available to referees at submission and to readers 
promptly upon request. Any restrictions on material availability or 
other relevant information must be disclosed in the manuscript’s 
Methods section and should include details of how materials and 
information may be obtained. 
 
Sequences, Structures and “Omics” 
Papers reporting protein or DNA sequences and molecular 
structures will not be accepted without an accession number 
to Genbank/EMBL/DDBJ, SWISS-PROT,  
ProteinDataBank, or other publicly available database in general 
use in the field that gives free access to researchers from the date of 
publication. 
 
Authors of papers describing structures of biological 
macromolecules must provide experimental data upon the request 
of Editor if they are not already freely accessible in a publicly 
available database such as ProteinDataBank, 
Biological Magnetic Resonance Databank, or Nucleic Acid 
Database. 
 
Human and Other Animal Experiments 
For primary research manuscripts reporting experiments on live 
vertebrates and/or higher invertebrates, the corresponding author 
must confirm that all experiments were performed in accordance 
with relevant guidelines and regulations.  
All manuscripts reporting animal research must be written up in 
accordance with the ARRIVE (Animal Research: Reporting In Vivo 
Experiments) guidelines – see http://www.nc3rs.org/ARRIVE. 
The manuscript must include in the Supplementary Information 
(methods) section (or, if brief, within of the print/online article at an 
appropriate place), a statement identifying the institutional and/or 
licensing committee approving the experiments, including any 
relevant details regarding animal welfare, patient anonymity, drug 
side effects and informed consent. 
For experiments involving human subjects, authors must identify 
the committee approving the experiments, and include with their 
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submission a statement confirming that informed consent was 
obtained from all subjects.  
 
 
Biosecurity Policy 
The Editor may seek advice about submitted papers not only from 
technical reviewers but also on any aspect of a paper that raises 
concerns. These may include, for example, ethical issues or issues of 
data or materials access. Occasionally, concerns may also relate to 
the implications to society of publishing a paper, including threats 
to security. In such circumstances, advice will usually be sought 
simultaneously with the technical peer-review process. As in all 
publishing decisions, the ultimate decision whether to publish is 
the responsibility of the editor of the journal concerned.  
 
Peer Review  
Manuscripts sent out for peer review are evaluated by at least one 
independent reviewer (often two or more). Authors are welcome to 
suggest independent reviewers to evaluate their manuscript, as 
well as request individuals or laboratories. All recommendations 
are considered, but it is at the Editor’s discretion their choice of 
reviewers. To expedite the review process, only papers that seem 
most likely to meet editorial criteria are sent for external review. 
Papers judged by the editors to be of insufficient general interest or 
otherwise inappropriate are rejected promptly without external 
review. The editors then make a decision based on the reviewers' 
evaluations:  
 
 Accept, with or without editorial revisions.  
 Revise, with the author addressing concerns raised by the 
reviewers before a final decision is reached. 
 Reject, but indicate to the authors that further work might 
justify a resubmission. 
 Reject outright, typically on grounds of specialist interest, 
lack of novelty, insufficient conceptual advance or major 
technical and/or interpretational problems. 
 
Anonymity and Confidentiality 
All details about submitted manuscripts are kept confidential and 
no comments are issued to outside parties or organizations about 
manuscripts under consideration or if they are rejected.  Editors are 
restricted to making public comments on a published article’s 
content and their evaluation.   
 
We do not release reviewers' identities to authors, except when 
reviewers specifically ask to be identified.  
 
We ask reviewers not to identify themselves to authors without the 
editor's knowledge. If they wish to reveal their identities while the 
manuscript is under consideration, this should be done via the 
editor; if this is not practicable, we ask authors to inform the editor 
as soon as possible after the reviewer has revealed their identity. 
We deplore any attempt by authors to confront reviewers or try to 
determine their identities. Our own policy is to neither confirm nor 
deny any speculation about reviewers' identities, and we encourage 
reviewers to adopt a similar policy. 
 
Upon accepting an invitation to evaluate a manuscript, reviewers 
must keep the manuscript and associated data confidential, and not 
redistribute them without the journal’s permission.  If a reviewer 
asks a colleague to assist in assessing a manuscript, confidentiality 
must be ensured and their names must be provided to the journal 
with the final report.   
 
 
 
Selecting Peer Reviewers 
Reviewer selection is critical to the publication process, and we base 
our choice on many factors, based on expertise, reputation, and 
specific recommendations.  A reviewer may decline the invitation to 
evaluate a manuscript where there is a perceived conflict of interest 
(financial or otherwise).               
                                                              
Communication with the Media 
Material submitted must not be discussed with the media. We 
reserve the right to halt the consideration or publication of a paper 
if this condition is broken. If a paper is particularly newsworthy, the 
press release will be sent to our list of journalists in advance of 
publication with an embargo that forbids any coverage of the 
manuscript, or the findings of the manuscript, until the time and 
date clearly stated. Authors whose papers are scheduled for 
publication may also arrange their own publicity (for instance 
through their institution’s press offices), but they must strictly 
adhere to our press embargo and are advised to coordinate their 
own publicity with our press office. 
 
Communication Between Scientists 
We do not wish to hinder communication between scientists. We 
ask you to communicate with other researchers as much as you 
wish, whether on a recognized community preprint server, by 
discussion at scientific meetings or by online collaborative sites such 
as wikis, but we do not encourage premature publication by 
discussion with the press (beyond a formal presentation, if at a 
conference).  
 
Pre- and Post-Submissions 
 
Authors are welcome to post pre-submission versions or the 
original submitted version of the manuscript on a personal blog, a 
collaborative wiki or a recognized preprint server (such as ArXiv) at 
any time (but not subsequent pre-accept versions that evolve due to 
the editorial process). 
For subscribed content, the accepted version of the manuscript, 
following the review process, may only be posted 6 months after 
the paper is published in an NPG journal. A publication reference 
and URL to the published version on the journal website must be 
provided on the first page of the postprint. The published version 
— copyedited and in the individual NPG journal format — may not 
be posted on any website or preprint server. 
For open access content published under a creative commons 
license, authors can replace the submitted version with the final 
published version at publication as long as a publication reference 
and URL to the published version on the journal website are 
provided. 
 
Correction and Retraction Process 
Content published as Advance Online Publication (AOP) is final 
and cannot be amended. The online and print versions are both part 
of the published record hence the original version must be 
preserved and changes to the paper should be made as a formal 
correction. If an error is noticed in an AOP article, a correction 
should accompany the article when it publishes in print. An HTML 
  Revised 24/02/2016 10 
(or full-text) version of the correction will also be created and 
linked to the original article. If the error is found in an article after  
 
print publication the correction will be published online and in the 
next available print issue. 
 
Please note the following categories of corrections to print and 
online versions of peer reviewed content: 
 Erratum. Notification of an important error made by the 
journal that affects the publication record or the scientific 
integrity of the paper, or the reputation of the authors, or of 
the journal. 
 Corrigendum. Notification of an important error made by 
the author that affects the publication record or the scientific 
integrity of the paper, or the reputation of the authors or the 
journal. 
 Retraction. Notification of invalid results. All co-authors 
must sign a retraction specifying the error and stating briefly 
how the conclusions are affected. 
 
Decisions about corrections are made by the Editor (sometimes with 
peer-reviewers' advice) and this sometimes involves author 
consultation. Requests to make corrections that do not affect the 
paper in a significant way or impair the reader's understanding of 
the contribution (a spelling mistake or grammatical error, for 
example) are not considered. 
 
In cases where co-authors disagree about a correction, the editors 
will take advice from independent peer-reviewers and impose the 
appropriate correction, noting the dissenting author(s) in the text of 
the published version. 
 
 
 
FURTHER INFORMATION 
 
 
For inquiries related to submission requirements, please contact the editorial office. For inquiries related to advertising, subscriptions, 
permissions, papers in production or publishing a supplement, please contact the publisher’s office.  
 
